{"id":"60d3337fe070","type":"article","url":"https://hartvaat.nl/2017/09/19/empagliflozine-en-vasculaire-functie-en-centrale-hemodynamiek-bij-diabetes-type-/","title":"Empagliflozine en vasculaire functie en centrale hemodynamiek bij diabetes type 2","title_en":"Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","canagliflozine","dapagliflozine","diabetes-en-hart","diabetes-type-2","empagliflozine","emperor-trials","obesitas","sglt2-remmers","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.117.029529","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.117.029529","authors":["Kristina Striepe","Agnes Jumar","Christian Ott","Marina V Karg","Markus P Schneider","Dennis Kannenkeril","Roland E Schmieder"],"significance":7,"published":"2017-09-19","source_date":"2017-09-19","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This mechanistic study demonstrated that empagliflozin improves vascular function and central hemodynamics in patients with type 2 diabetes, providing pathophysiological insights into the cardiovascular benefits of SGLT2 inhibition beyond glucose lowering.","created":"2026-07-03T10:26:53Z","updated":"2026-07-03T13:26:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar de effecten van empagliflozine op vaatfunctie en centrale hemodynamiek bij diabetes type 2. Mechanistisch inzicht in de cardiovasculaire voordelen van SGLT2-remming voorbij glucoseverlaging.","abstract_original":""}